The OSUCCC Clinical Trials Office (CTO), rated """"""""Excellent to Outstanding"""""""" in the 1999 review, supports the centralized administration of protocol conduct, development, review, implementation, monitoring, regulatory compliance, and quality assurance. The CTO is a shared resource of the OSUCCC that provides centralized management of all clinical trials conducted within the OSUCCC. The mission of the CTO is to foster a supportive environment conducive to the conduct of clinical trials by OSUCCC members and to provide a centralized resource to OSUCCC investigators for protocol administration, tracking and monitoring, data management, regulatory guidance, and financial management necessary for the successful conduct of clinical trials in a methodologically-sound, expedient, and cost-effective manner. The CTO came under the medical leadership o! John Byrd, M.D., and administrative leadership of Susan Ebert, R.D., M.S., in 2001. Since that time, the clinical research staff of Radiation Oncology, Stem Cell Transplant Program, Head &Neck Oncology, The Cancer and Leukemia Group B (CALGB), The AIDS-Related Malignancy Consortium (AMC), The CLL Research Consortium, and The NCI/CTEP Phase I Program have been consolidated within the CTO. This effort of consolidation as well as new clinical research faculty recruits and a consequent 232% increase in accrual to investigator-initiated studies (580 in 1999 and 1,926 in 2003) has resulted in the current CTO staffing of 38.5 FTE for its 224 open protocols, including 12 funded through NCI R21 QuickTrial grants. With recent acquisition of 7,000 nsf of space for the CTO, plans are to consolidate 20 remaining research staff conducting select cooperative group trials (ACOSOG, NSABP, and GOG) over the next two years in order to finalize centralization of all cancer clinical research activities. The CTO has reinforced infrastructure in the past several years with the creation of two new position titles, Regulatory Coordinator and Financial Manager. In addition, management infrastructure was improved with the creation of two new supervisory roles, the Clinical Research Manager (who manages all research nurses) and Data Management Supervisor (who manages research associates). A new web-based Cancer Research Information System (CRIS) has been developed for use by the CTO staff that vastly improves tracking of all research activities and provides the OSUCCC leadership and membership with the tools to monitor progress;2627 patients were entered on trials and registered into the CTO CRIS database during the most recent 12-month period.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-34
Application #
7743469
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
2010-11-30
Budget Start
2008-12-01
Budget End
2010-11-30
Support Year
34
Fiscal Year
2009
Total Cost
$353,508
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Orchard, Tonya S; Andridge, Rebecca R; Yee, Lisa D et al. (2018) Diet Quality, Inflammation, and Quality of Life in Breast Cancer Survivors: A Cross-Sectional Analysis of Pilot Study Data. J Acad Nutr Diet 118:578-588.e1
Reiff, Sean D; Mantel, Rose; Smith, Lisa L et al. (2018) The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation. Cancer Discov 8:1300-1315
Herman, Joseph M; Jabbour, Salma K; Lin, Steven H et al. (2018) Smad4 Loss Correlates With Higher Rates of Local and Distant Failure in Pancreatic Adenocarcinoma Patients Receiving Adjuvant Chemoradiation. Pancreas 47:208-212
Qian, Maoxiang; Cao, Xueyuan; Devidas, Meenakshi et al. (2018) TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children. J Clin Oncol 36:591-599
Myers, Regina M; Hill, Brian T; Shaw, Bronwen E et al. (2018) Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b-cell lymphoma. Cancer 124:816-825
Nemeth, Julianna M; Thomson, Tiffany L; Lu, Bo et al. (2018) A social-contextual investigation of smoking among rural women: multi-level factors associated with smoking status and considerations for cessation. Rural Remote Health 18:4338
Mace, Thomas A; Shakya, Reena; Pitarresi, Jason R et al. (2018) IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. Gut 67:320-332
Massengill, James B; Sample, Klarke M; Pilarski, Robert et al. (2018) Analysis of the exome aggregation consortium (ExAC) database suggests that the BAP1-tumor predisposition syndrome is underreported in cancer patients. Genes Chromosomes Cancer 57:478-481
Buteyn, Nathaniel J; Fatehchand, Kavin; Santhanam, Ramasamy et al. (2018) Anti-leukemic effects of all-trans retinoic acid in combination with Daratumumab in acute myeloid leukemia. Int Immunol 30:375-383
Hamilton, C A; Miller, A; Casablanca, Y et al. (2018) Clinicopathologic characteristics associated with long-term survival in advanced epithelial ovarian cancer: an NRG Oncology/Gynecologic Oncology Group ancillary data study. Gynecol Oncol 148:275-280

Showing the most recent 10 out of 2602 publications